

Redeye Interview: Neola Medical Strengthens Ownership Base with Institutional Investors

In an interview with Redeye, CEO Hanna Sjöström, discusses the company's latest capital raise of approximately SEK 20 million and its significance for the future. For the first time, the company has attracted institutional investors, Cicero Funds and Adrigo Funds, while existing major shareholders, including Anmiro AB, have continued to increase their holdings.

Watch the full interview where CEO Hanna Sjöström shares insights into what makes Neola Medical an attractive investment opportunity and how the capital will be utilized to finance the company's clinical studies and the planned FDA application.

Watch the full interview here: Redeye Interview with CEO Hanna Sjöström

## For further information, contact:

Hanna Sjöström, CEO

e-mail: hanna.sjostrom@neolamedical.com

## **About Neola Medical**

Neola Medical AB (publ) develops revolutionizing medical technology device for non-invasive continuous lung monitoring and real-time alerts of life-threatening lung complications of preterm born infants. Immediate detection of complications provides the possibility of early treatment, improved health care and healthier lives for preterm born infants. The patented cutting-edge technology is developed at Lund University in Sweden and based on a spectroscopic method that measures lung volume changes and oxygen gas concentration. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

## **Image Attachments**

Redeye Interview Neola Medical Strengthens Ownership Base With Institutional Investors

## **Attachments**

Redeye Interview: Neola Medical Strengthens Ownership Base with Institutional Investors